2CHEN Hong1,CHEN Qun2,FANG Ming3 & MI Yan1 1 The First Affiliated Hospital of Harbin Medical University,Harbin 150101,China,2 Harbin Acheng District People’s Hospital,Harbin 150300,China,3 Graduate Department of Harbin Medical University,Harbin 150001,China.microRNA-181b targets MLK2 in HL-60 cells[J].Science China(Life Sciences),2010,53(1):101-106. 被引量：20
二级参考文献39
1Phelan D R,Price G,Liu Y F,et al.Activated JNK phosphorylates the c-terminal domain of MLK2 that is required for MLK2-induced apoptosis. Journal of Biological Chemistry . 2001
2Bartel DP.MicroRNAs: genomics, biogenesis, mechanism and function. Cell . 2004
3Tran SE,Holmstrom TH,Ahonen M,Kahari VM,Eriksson JE.MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. Journal of Biological Chemistry . 2001
4Robinson MJ,Cobb MH.Mitogen-activated protein kinase pathways. Current Opinion in Cell Biology . 1997
5Lowenberg B,Downing JR,Burnett A.Acute myeloid leukemia. New England Journal of Medicine, The . 1999
6Whitman S P,Archer K J,Feng L,et al.Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research . 2001
7Xie X,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promoters and 3’UTRs by comparison of several mammals. Nature . 2005
8Lewis B P,Burge C B,Bartel D P.Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell . 2005
9Wheatley K,Burnett AK,Goldstone AH eta1.A simple,robust,validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derivedfrom the MRC AML 10 trial.United Kingdom Medical Research Council‘ s Adult and Childhood Leukemia Working Parties. British Journal of Haematology . 1999
10Kottaridis P D,Gale R E,Frew M E,et al.The presence ofa Flt-3internal tandem duplication in patients with acutemyeloid leukemia(AML)adds important prognosticinformation to cytogenetic risk group and response to the firstcycle of chemotherapy:. Blood . 2001
1D~ring Y, Soehnlein O, Weber C. Neutrophils cast NETs in atherosclerosis: employing peptidylarginine deiminase as a therapeutic target[J]. Circ Res, 2014,114 (6) : 931 934.
2Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk {actor for coronary heart disease= a systematic review and meta analyses for the U. S. Preventive Services Task Force [J]. Ann Intern Med, 2009,151 (7) : 483-495.
3Bhat T, Tell S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review [J]. Expert Rev Cardiovasc Ther, 2013,11 ( 1 ) = 55-59.
4Packard RR, Libby P. Inflammation in atherosclerosis.- from vascular biology to biomarker discovery and risk prediction [J]. Clin Chem,2008,54(l) :24-38.
5Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice[J]. J Am Coil Cardiol, 2009,54(23) : 2129-2138.
6Hansson GK, Hermansson A. The immune system in atherosclerosis[J]. Nat Immunol,2011,12(3) :204-212.
7Mayer FJ, Gruenberger D, Schillinger M, et al. Prognostic value of neutrophils in patients with asymptomatic carotid artery disease[J]. Atherosclerosis,2013,231(2)..274-280.
8Guasti L, Dentali F, Castiglioni L, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects[J]. Thromb Haemost, 2011,106 (4)=591 599.
9Home BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? [J]. J Am 12011 Cardiol, 2005,45 (10) : 1638-1643.
10Madjid M, Awan I, Willerson JT, et al. Leukocyte count and coronary heart disease: implications for risk assessment [J]. J Am Coll Cardiol,2004,44(10) : 1945-1956.
